The invention is relative to the use of an effective amount of an agonist of the CDOs apoptotic function for the preparation of a drug to induce cell apoptosis in a patient having tumoral cells bearing CDO and expressing SHH. The agonist may be a CDO fragment, a fusion protein comprising a CDO fragment, an antibody against SHH, or a siRNA which is capable of inhibiting SHH expression. The invention also concerns a pharmaceutical composition containing an agonist of the CDOs apoptotic function or a CDO polypeptide or an antibody specific to CDO, and an agonist of the PTC1s apoptotic function or a PTC1 polypeptide or an antibody specific to PTC1, and a pharmaceutically acceptable excipient or vehicle.
